202 related articles for article (PubMed ID: 17131059)
21. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
22. A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.
Hamidah NH; Farisah NR; Azlinda AB; Wong FL; Das S; Fadillah SA; Ainoon O
Clin Ter; 2012; 163(2):109-13. PubMed ID: 22555824
[TBL] [Abstract][Full Text] [Related]
23. BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.
Chang CC
Arch Pathol Lab Med; 2006 Aug; 130(8):1123-5. PubMed ID: 16879012
[No Abstract] [Full Text] [Related]
24. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Tefferi A; Gilliland DG
Mayo Clin Proc; 2005 Jul; 80(7):947-58. PubMed ID: 16007902
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
26. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
27. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
[TBL] [Abstract][Full Text] [Related]
28. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
29. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase fusion genes in chronic myeloproliferative diseases.
Cross NC; Reiter A
Leukemia; 2002 Jul; 16(7):1207-12. PubMed ID: 12094244
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Zhao R; Follows GA; Beer PA; Scott LM; Huntly BJ; Green AR; Alexander DR
N Engl J Med; 2008 Dec; 359(26):2778-89. PubMed ID: 19109573
[TBL] [Abstract][Full Text] [Related]
32. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
[TBL] [Abstract][Full Text] [Related]
33. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
Speletas M; Katodritou E; Daiou C; Mandala E; Papadakis E; Kioumi A; Ritis K; Korantzis I
Leuk Res; 2007 Aug; 31(8):1053-62. PubMed ID: 17045648
[TBL] [Abstract][Full Text] [Related]
34. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
James C; Ugo V; Le Couédic JP; Staerk J; Delhommeau F; Lacout C; Garçon L; Raslova H; Berger R; Bennaceur-Griscelli A; Villeval JL; Constantinescu SN; Casadevall N; Vainchenker W
Nature; 2005 Apr; 434(7037):1144-8. PubMed ID: 15793561
[TBL] [Abstract][Full Text] [Related]
35. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL; Pardanani A; Tefferi A; Gilliland DG
Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
[TBL] [Abstract][Full Text] [Related]
36. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
Langabeer SE; Ni Ainle F; Conneally E; Lawler M
Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
[TBL] [Abstract][Full Text] [Related]
37. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
38. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
Nelson ME; Steensma DP
Leuk Lymphoma; 2006 Feb; 47(2):177-94. PubMed ID: 16321848
[TBL] [Abstract][Full Text] [Related]
39. JAK2 in myeloproliferative disorders is not just another kinase.
Tefferi A; Gilliland DG
Cell Cycle; 2005 Aug; 4(8):1053-6. PubMed ID: 15970705
[TBL] [Abstract][Full Text] [Related]
40. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
